Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Capital Expenditures (2019 - 2025)

AVITA Medical's Capital Expenditures history spans 7 years, with the latest figure at $485000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 94.47% year-over-year to $485000.0; the TTM value through Dec 2025 reached $635000.0, down 93.08%, while the annual FY2025 figure was $635000.0, 93.08% down from the prior year.
  • Capital Expenditures reached $485000.0 in Q4 2025 per RCEL's latest filing, up from -$595000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $8.8 million in Q4 2024 to a low of -$805000.0 in Q2 2024.
  • Average Capital Expenditures over 5 years is $595944.4, with a median of $89995.5 recorded in 2023.
  • Peak YoY movement for Capital Expenditures: surged 12744344.44% in 2024, then crashed 1015.38% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $27000.0 in 2021, then surged by 1548.15% to $445000.0 in 2022, then plummeted by 33.48% to $296000.0 in 2023, then skyrocketed by 2860.81% to $8.8 million in 2024, then tumbled by 94.47% to $485000.0 in 2025.
  • Per Business Quant, the three most recent readings for RCEL's Capital Expenditures are $485000.0 (Q4 2025), -$595000.0 (Q3 2025), and $524000.0 (Q2 2025).